G1 Therapeutics rises on positive data from breast cancer therapy trial

G1 Therapeutics

08/01/2024 18:01

** Shares of cancer drug developer G1 Therapeutics Inc 
 GTHX.O  rise ~17% to $3.39 
    ** Co says its experimental combination therapy being
developed to treat a type of breast cancer helped prolong the
lives of patients, according to preliminary data from a
mid-stage study  
    ** GTHX' trilaciclib in combination with Gilead Sciences'
 GILD.O  Trodelvy is being tested in patients with metastatic
triple-negative breast cancer       
     ** Company expects to provide updated data from the study
mid-2024
    ** Cosela was approved by the U.S. health regulator in 2021
to reduce the occurrence of a common, harmful side effect of
chemotherapy 
    **  Company expects ~$82 million in cash, cash equivalents,
and marketable securities as of Dec. 31, 2023, to extend into
2025
    ** GTHX shares fell ~44% in 2023

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))